EAST WINDSOR, N.J. -- NexMed, Inc. announces the following Webcast:
What: NexMed, Inc. Informed Investors Webcast
When: March 15, 2007 @ 11:00 AM Eastern
Where: http://www.informedinvestors.com/IIF/IIF_Client.asp?clientID=42786
How: Live over the Internet -- Simply log on to the web at the address above.
Contact: Mark Westgate, CFO (609) 371-8123 x159 or mwestgate@nexmed.com
If you are unable to participate during the live webcast, the call will be available for replay at http://www.vcall.com/ClientPage.asp?ID=114560 or http://www.investorcalendar.com/
NexMed, Inc., founded in 1995 and based in East Windsor, NJ, is an emerging specialty pharmaceutical and drug delivery technology company currently developing innovative pharmaceutical products based on its NexACT[R] transdermal drug delivery platform technology. NexACT[R] enables drugs to be better absorbed through the skin. This may provide a highly effective topical approach to diseases currently being treated by systemic (oral or injectable) therapies. Drugs delivered topically with NexACT[R] are expected to improve therapeutic outcomes and reduce or eliminate systemic side effects that often accompany oral or injectable medications. NexMed's lead product is Alprox-TD[R], which has completed two pivotal Phase 3 studies. Alprox-TD[R] is a topical formulation that incorporates alprostadil, a vasodilator, with the NexACT[R] delivery technology for the treatment of male Erectile Dysfunction. The Company is also developing Femprox[R], a topical formulation that incorporates alprostadil with the NexACT[TM] technology for the treatment of Female Sexual Arousal Disorder. In September 2005, NexMed entered into an exclusive, global licensing agreement with Novartis International Pharmaceutical Ltd., for its proprietary NM100060 nail lacquer treatment for onychomycosis, commonly known as nail fungus. It is anticipated that Novartis will initiate a Phase 3 study during the second half of 2006. Under the terms of the agreement, NexMed will receive up to $51 million, including upfront and milestone payments based on the achievement of specific development and regulatory milestones. Additionally, NexMed will receive royalties on product sales. NexMed's strategy includes pursuing partnerships with other pharmaceutical companies regarding the incorporation of its NexACT[R] technology with established brands, with the goal of extending product patent life while enhancing efficacy and patient compliance.
No comments:
Post a Comment